January 23, 2018

Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.

Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.

September 19, 2017

New Research Shows People on Insulin For Diabetes Maintain A1C Reductions Through Digital Therapy Management

A study presented at EASD 2017 shows long-term A1C reductions through personalized insulin dose adjustments every eight weeks using Glytec’s therapy management software.

More than 50 percent of all people using insulin to manage diabetes are not at their target A1C, which is why this high-risk population is a primary focus of value-based care strategies among providers and payers alike. A retrospective study presented at the Annual Meeting of the European Association for the Study of Diabetes shows that patients whose insulin therapy is guided by Glytec’s FDA-cleared Glucommander™ software not only achieve glucose control rapidly, but with ongoing personalized dose adjustments, successfully maintain A1C reductions long term.

June 7, 2017

Case Studies Presented at Diabetes Technology Society Conference Highlight Millions in Hospital Cost Savings with Improved Glucose Control

One study presented at the International Hospital Diabetes Meeting observed first-year cost savings of nearly $7.5 million stemming from adoption of best practice for insulin therapy.

A series of studies and presentations included in the 6th International Hospital Diabetes Meeting highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia (< 40 mg/dL) in the acute care setting. With thirty to forty percent of ALL hospitalized patients requiring insulin therapy, not just those with diabetes, the common problem of insulin mismanagement has significant impact on care quality, patient safety and patient experience, as well as cost and value.

May 8, 2017

Computer-Guided Insulin Titration Helps Hospitals Meet Basal Bolus Standard, Study Finds

An analysis of an electronic glucose management system developed by Glytec, which helps nurses safely manage basal bolus insulin dosing in the hospital, was presented at the recent meeting of the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress, held in Austin, Texas.

The movement toward quality ratings — and an increased emphasis on preventing readmissions — demanded solutions that help hospitals achieve the standard, which ADA clarified in January 2017 to state that basal bolus insulin was the preferred treatment for noncritically ill patients, and that, “Prolonged sole use of sliding scale insulin in the inpatient hospital setting is strongly discouraged.”

February 16, 2017

New Research Further Validates Benefits of Personalized Diabetes Therapy Management Across the Continuum of Care

Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.

The 10th Annual International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) showcases additional evidence that use of Glytec’s patented eGlycemic Management System®, or eGMS®, leads to dramatic improvements in diabetes control and patient outcomes in both acute and outpatient settings. Two studies presented by diabetologist and researcher, Dr. Bruce Bode, find that personalized therapy management facilitated through Glytec’s eGMS® effectively reduces hemoglobin A1C, incidence of hypoglycemia and time to prescribed glucose target, all primary measures of diabetes control and patient outcomes.

January 25, 2017

Grady Health System Improves Diabetes Care With Glytec’s eGlycemic Management System

Glytec’s system for personalized diabetes therapy management translates to better quality of care at Atlanta’s Grady Health System.

In its quest to ensure high quality care for critically ill patients, Atlanta’s Grady Health System has implemented the evidence-based Glytec eGlycemic Management System® (eGMS®), a personalized diabetes therapy management solution.

November 14, 2016

Dramatic Readmission Reductions for CABG, CHF and AMI Attributed to Glytec’s eGlycemic Management System

Two studies presented at the 16th Annual Diabetes Technology Meeting showcase readmission reductions as high as 68% with Glytec’s solution.

Two new studies presented at last week’s Diabetes Technology Meeting further validate the ability of Glytec’s eGlycemic Management System® (eGMS®) to achieve dramatic readmission reductions for patient populations at the center of new at-risk and value-based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).

September 30, 2016

Hawaii Pacific Health Receives 2016 HIMSS Enterprise Davies Award Based in Part on Success With Glytec’s eGMS®

Our client, Hawaii Pacific Health, was named a HIMSS Enterprise Davies Award recipient based in part on its success implementing Glytec’s eGlycemic Management System® to support computer-based insulin dosing and a new hypoglycemia protocol.

The results were better glucose control with computer-directed insulin dosing system versus usual care. 39.8% of all glucose values in the ICU setting were above the recommended limit (glucose 180 mg/dl) with usual care. With computer-directed insulin dosing system for intravenous insulin, the hyperglycemia rate was much lower representing just 16.6% of all glucose values.

July 8, 2016

Reduced Inpatient Hypoglycemia With Electronic Glycemic Management System

An electronic glycemic management system (eGMS) may help lower rates of hypoglycemia and lower average blood glucose levels in hospitalized patients compared with usual care, according to a new study.

The aim of this study was to compare hypoglycemia rates in patients managed with an eGMS compared with patients managed by usual care. In this current study, there were 45,335 patients treated with usual care and 13,351 patients treated with eGMS. The target blood glucose was pegged at 100 mg/dL to 180 mg/dL. The researchers evaluated how many patients experiencing mild to moderate hypoglycemia (<70 mg/dL, <60 mg/dL, and <50 mg/dL) and severe hypoglycemia (<40 mg/dL) in the eGMS group compared with the usual care group.

July 2, 2016

Electronics Said to Reduce Hypoglycemic Events

New data presented at AACE shows hypoglycemic events are less likely in patients with diabetes treated with an electronic glycemic management system.

In an interview, Joseph Aloi, MD, section chief of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, told Diabetes in Control that, “Patients who were treated with the [electronic glycemic management system] had a statistically lower incidence of hypoglycemic events and lower average blood glucose compared with [usual care], suggesting it may be easier to achieve glycemic targets safely for patients in the hospital setting.

June 20, 2016

Glytec Presents Evidence on How Using Data to Deliver Insulin Improves Outcomes

Using an algorithm to recommend insulin dosing, both in and out of the hospital, was shown to improve glycemic control and aid population health management.

The march toward value-based care is occurring on many fronts, with diabetes quality metrics front and center. Providers from giant hospital systems to primary care practices are looking for ways to find savings—and make patients healthier. In this mix is Glytec, a 10-year-old company founded on the idea that taking guesswork and time out of insulin dosing, first in hospital settings and then outside them, could dramatically reduce episodes of hypo- and hyperglycemia. This would provide savings and lead to better glycated hemoglobin (A1C) levels for patients with previously uncontrolled diabetes.

June 16, 2016

Electronic Glycemic Management System Reduces Hypoglycemic Event Rate

Hypoglycemic events are less likely in inpatients with diabetes treated with an electronic glycemic management system compared with usual care, according to data presented here.

“Patients who were treated with the [electronic glycemic management system] had a statistically lower incidence of hypoglycemic events and lower average blood glucose compared with [usual care], suggesting it may be easier to achieve glycemic targets safely for patient in the hospital setting,” Joseph Aloi, MD, section chief of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, told Endocrine Today.

Glytec’s Glucommander and eGlycemic Management System Featured in Five Studies Presented at The American Diabetes Association’s 76th Scientific Sessions

Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.

June 1, 2016

Glytec Presents Key Studies at the AACE 25th Annual Scientific and Clinical Congress

Experts demonstrate the ability of automated glucose management to significantly reduce rates of hypoglycemia and DKA.

Glytec, the pioneer and leader in providing innovative, FDA cleared glucose management software solutions, today announced that two abstracts addressing the approach to care for patients suffering from hypoglycemia and diabetic ketoacidosis (DKA) were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress, held from May 25-29th in Orlando, Florida.

May 31, 2016

Computer Algorithms Managing Insulin Dosages Result in Better Glycemic Control

When insulin dosages are calculated using computer algorithms to reach target blood glucose levels, hospitalized patients are less likely to have episodes of low blood sugar and recover sooner from diabetic ketoacidosis than when insulin dosages are calculated without an algorithm.

Those were key findings from two multisite studies presented at the American Association of Clinical Endocrinologists meeting, held May 25-29 in Orlando, Florida. “Computer algorithms facilitate doing the right thing,” said Dr. Joseph A. Aloi, professor of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and the studies’ principal investigator.

May 16, 2016

Orange Regional Medical Center Receives HIMSS Stage 7 Award Based Largely on Glytec’s Insulin Decision Support Solution

Our client, Orange Regional Medical Center, received a HIMSS Analytics Stage 7 Award based largely on its success implementing Glytec’s eGlycemic Management System® to support computer-based precision insulin dosing.

HIMSS Analytics® awarded Orange Regional Medical Center (ORMC), in Middletown, N.Y., with a Stage 7 Award. The award represents ORMC’s attainment of the highest level on the Electronic Medical Record Adoption Model (EMRAM)℠.

October 5, 2015

Study: Insulin Dosing Platform Helped Reduce Post-Cardiac Surgery Complications

Intensive insulin therapy, with the help of a patient-specific IV insulin dosing platform, helped reduce post-cardiac surgery complications, according to a new study from Emory University.

A total of 302 patients were looked at after coronary artery bypass graft (CABG) surgery. Results demonstrated that providing more precise insulin dosing via the Glucommander IV led to improved glycemic control and a significant reduction in the rate of hypoglycemia, which is a common side effect of intensive insulin therapy in patients undergoing cardiac surgery.

September 29, 2015

New Study Demonstrates That Improvements in Glucose Control Reduced Complications After Heart Surgery

Study from Emory University published in Diabetes Care leverages Glytec’s Glucommander IV platform to evaluate the optimal level of glycemic control needed to improve outcomes.

Glytec, the pioneer and leader in providing innovative glucose management software solutions central to effective diabetes management, is pleased to share the results of the GLUCO-CABG trial conducted by Emory University, which demonstrated intensive insulin therapy resulted in a reduction in post cardiac surgery complications. Hyperglycemia is common in patients undergoing cardiac surgery, reported in 60-90 percent of patients with a known history of diabetes and in more than half of patients without diabetes.

June 8, 2015

Glytec Presents Several Research Studies at the ADA 75th Scientific Sessions

Data continue to validate the benefits of standardized glycemic management through computerized decision support for both IV and subcutaneous insulin dosing.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution® (eGMS®) have been selected as poster presentations at the American Diabetes Association 75th Scientific Sessions. The 75th Scientific Sessions, taking place from June 5-9th in Boston, are the premier venue for exchanging news and showcasing innovation to the diabetes community.

June 4, 2015

37 More Hospitals Elect to Strengthen Their Diabetes Management Programs with Glytec

Company continues dramatic growth driven by its unprecedented, proven results.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, announces 13 additional health systems across the U.S. have recently selected the company’s eGlycemic Management System® (eGMS®). Collectively, they represent 37 new hospital implementations. eGMS® enables providers, payers, and patients to control glucose levels, and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.